Enemac 16.1+ 6 / 100ml

Rectal Solution

Active principles

100 ml contain: Active ingredients: monosodium phosphate monohydrate 16.10 g; disodium phosphate heptahydrate 6 g. Excipients: FU purified water to taste Excipients with known effects: sodium methyl p-hydroxybenzoate 0.104 g. For the full list of excipients, see section 6.1.

Excipients

Sodium methyl p-hydroxybenzoate Purified water FU

Therapeutic indications

Constipation. Bowel evacuation before radiological or other diagnostic tests.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Anorectal affections.

Dosage

Posology It is administered rectally only. Adults: 1 bottle of ENEMAC per day. Children over 2 years: half or a quarter of the adult dose. Do not exceed the recommended dose. Method of administration Remove the screw cap and screw in the supplied cannula. Lubricate the latter with a few drops of ENEMAC lie down on the left side and gently introduce it into the rectum. Squeeze the bottle to release the liquid and extract it while holding it down. Keep the liquid in a lying position, until you feel the urgent need to evacuate (about 5 minutes): there is no need to hold back more than 10-15 minutes.

Warnings and Precautions

In children over two years of age, the cannula should not penetrate more than half of its length. In the cold season it is recommended to bring the product to room temperature by heating it in a bain-marie. Use in occasional administrations. Do not use in children under two years of age unless under medical supervision. The continued use of laxatives can cause addiction or damage of various kinds. Do not use laxatives if abdominal pain, nausea and vomiting are present. If constipation is persistent, see your doctor. Prolonged use can induce a state of dehydration. The product contains sodium salts in the amount indicated above; this is taken into account in the case of a low-sodium diet.

Interactions

No interactions with other drugs have been reported so far.

Side effects

Prolonged use can induce a state of dehydration. The patient is invited to communicate to his doctor or pharmacist the onset of any undesirable effect that may appear in case of use. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.

Pregnancy and breastfeeding

Use during pregnancy is not contraindicated.